Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 10/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.30 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22286615 | 0.92 | SLC10A2 (0.41) | SLC10A2NR1H4 | |
| SCHEMBL22286457 | 0.92 | SLC10A2 (0.41) | SLC10A2NR1H4 | |
| SCHEMBL22286590 | 0.92 | SLC10A2 (0.41) | SLC10A2NR1H4 | |
| SCHEMBL22286481 | 0.89 | SLC10A2 (0.37) | SLC10A2NR1H4CYP2C19LMNALTB4R | |
| SCHEMBL22286555 | 0.87 | NR1H4 (0.43) | SLC10A2NR1H4CYP2C19LMNALTB4R | |
| SCHEMBL22336329 | 0.83 | CYP2C19 (0.33) | SLC10A2CYP2C19LMNAFFAR4RXRA | |
| SCHEMBL22336276 | 0.83 | CYP2C19 (0.33) | SLC10A2CYP2C19LMNAFFAR4RXRA | |
| SCHEMBL22286480 | 0.83 | SLC10A2 (0.42) | SLC10A2 | |
| SCHEMBL22286595 | 0.83 | SLC10A2 (0.42) | SLC10A2 | |
| SCHEMBL22286602 | 0.83 | SLC10A2 (0.42) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | claimed |
| EP-3921027-B1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2023-07-19 | — | — | EP | claimed |
| EP-3921027-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | Albireo AB (SE) | 2021-12-15 | — | — | EP | claimed |
| US-10975045-B2 | Benzothiazepine compounds and their use as bile acid modulators | Aibireo AB (SE) | 2021-04-13 | — | — | US | claimed |
| WO-2020161216-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-13 | — | — | WO | claimed |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-06 | — | — | US | claimed |
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | disclosed |
| EP-3921027-B1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2023-07-19 | — | — | EP | disclosed |
| EP-3921027-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | Albireo AB (SE) | 2021-12-15 | — | — | EP | disclosed |
| US-20210147372-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-05-20 | — | — | US | disclosed |
| US-10975045-B2 | Benzothiazepine compounds and their use as bile acid modulators | Aibireo AB (SE) | 2021-04-13 | — | — | US | disclosed |
| WO-2020161216-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 6/4885CYP2C19 347/4885 |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 6/4885CYP2C19 347/4885 |
| US-20210147372-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 6/4885CYP2C19 347/4885 |
| US-10975045-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 6/4885CYP2C19 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.